Tyra Biosciences is a clinical-stage biopharmaceutical company developing precision medicines that target the FGFR pathway. Its pipeline centers on oral FGFR inhibitors, including programs aimed at FGFR3-driven cancers and other solid tumors as well as selected skeletal conditions. The company serves an oncology and rare-disease niche where genetically defined patient populations are the focus of drug development.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -28.1 | — |
| Q2 2025 | 0 | — | -28.1 | — |
| Q3 2025 | 0 | — | -29.9 | — |
| Q4 2025 | 0 | — | -33.8 | — |
| Q1 2026 | 0 | — | -39.3 | — |
| Q2 2026 | 0 | — | -45.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Napco Security Technologies, Inc. (NSSC), Old Second Bancorp, Inc. (OSBC), The RealReal, Inc. (REAL), BJ's Restaurants, Inc. (BJRI), Freenome, Inc. (FRNM), GH Research PLC (GHRS)